Skip to main content
. 2019 Aug 26;37(30):2769–2777. doi: 10.1200/JCO.18.01972

FIG 4.

FIG 4.

(A) Event-free survival for patients with stage III/IV disease with combined loss of heterozygosity of chromosomes 1p and 16q treated in AREN0533 compared with National Wilms Tumor Study 5 (NWTS-5). (B) Overall survival for patients with stage III/IV disease with combined loss of heterozygosity of chromosomes 1p and 16q treated in AREN0533 compared with NWTS-5.